Within the background of the global economy, the authors evaluate competition among domestic firms, and ascertain impact on the domestic pharmaceutical industry. This paper analyzes the industry's structure, conduct and performance to show that the pharmaceutical industry did not escape the effects of free trade areas and global competition, despite the general view that it is a high-profit industry. The U.S. government aided the industry in the areas of lengthening of patents life, allowing mergers, and the negotiation of international property rights. Also, firms have come to embrace increased rivalries in the areas of non-price tactics. We found small firms reacting to a leader, such as Merck, previous R&D and advertising outlays, and that they find a haven in the area of generics rather then basic research. The industry embraces an array of price strategies, relating to generics and the lack of information about prices at home, and unfair competition from abroad, an area where the government could play a larger role. Several hypotheses based on the literature have been advanced to ascertain these results.
Get full access to this article
View all access options for this article.
References
1.
AgrawalM., Global Competitiveness in the Pharmaceutical Industry, (Binghamton, NY: The Haworth Press, 1999).
2.
BalanceR.PoganyJ.ForstnerH., The World's Pharmaceutical Industries: An International Perspective on Innovation, Competition, and Policy, (Aldershot, England: Edward Elgar Publishing Ltd., 1992).
3.
BerndtE.R.PindyckR.S.AzoulayP., “Consumption Externalities and Diffusion in Pharmaceutical Markets: Antiulcer Drugs,”NBER Working Paper7772, June 2000.
4.
BerndtE.R.CockburnI.M.GrilichesZ., “Pharmaceutical Innovations and Market Dynamics: Tracking Effects on Price Indexes for Antidepressant Drugs,”Brookings Papers on Economic Activity, 1997, pp. 133–199.
5.
CavesR.E.WhinstonM.D.HurwitzM.A., “Patent Expiration, Entry, and Competition in the U.S. Pharmaceutical Industry,”Brookings Papers on Economic Activity, 1991, pp. 1–45.
6.
ChoiJ.P., “Herd Behavior, The “Penguin Effect,” and the Suppression of Informational Diffusion: An Analysis of Informational Externalities and Payoff Interdependency,”The RAND Journal of Economics, Volume 28, Number 3, Autumn 1997, pp. 403–425.
7.
→ ComanorW.S., “The Political Economy of the Pharmaceutical Industry,”Journal of Economic Literature, Volume 24, Issue 3, September 1986, pp. 1178–1217.
8.
DanzonP. M., Pharmaceutical Price Regulation, (Washington, DC: The AEI Press, 1997).
9.
DunningJ.H., “International Direct Investment in Innovation: The Pharmaceutical Industry,” InMultinationals, Technology, and Competitiveness, (London: Unwin Hyman, 1988).
10.
→ EllisonS.F.CockburnI.GrilichesZ.HausmanJ., “Characteristics of Demand for Pharmaceutical Products: An Examination of Four Cephalosporins,”The RAND Journal of Economics, Volume 28, Number 3, Autumn 1997, pp. 426–446.
11.
FrankR.G.SalkeverD., “Pricing, Patent Loss and the Market for Pharmaceuticals,”Southern Economic Journal, Volume 59, Number 2, October 1992, pp. 165–179.
12.
FudenbergD.TiroleJ., Game Theory, (Cambridge, MA: The MIT Press, 1993).
13.
GrabowskiH., “The Determinants of R and D in Three Industries,”Journal of Political Economy, Volume 76, 1968.
14.
→ GrabowskiHenryG.NevinsD. Baxter, “Rivalry in Industrial Research and Development,”The Journal of Industrial Economics, Volume 21, Number 3, 1973, pp. 209–235.
15.
GrabowskiH.MuellerD.C., “Non-Price Competition in the Cigarette Industry,”The Antitrust Bulletin, Volume 14, 1969, pp. 607–628.
16.
GrabowskiH.MuellerD.C., “Non-Price Competition in the Cigarette Industry: A Comment, The Antitrust Bulletin, Volume 14, 1970, pp. 679–686.
17.
GrabowskiH.G.MuellerD.C., “Imitative Advertising in the Cigarette Industry,”The Antitrust Bulletin, Volume 16, Summer 1971, pp. 257–292.
18.
GrabowskiH.G.VernonJ.M., “Innovation and Invention: Consumer Protection Regulation in Ethical Drugs,”AER Proceedings, Volume 67,” Number 1, 1977, pp 359–364.
19.
→ GrabowskiH.G.VernonJ.M., “A New Look at the Returns and Risks of Pharmaceutical R&D,”Management Science, Volume 36, July 1990, pp. 804–821.
20.
→ GrabowskiH.G.BaxterN.D., “Rivalry in Industrial Research and Development,”The Journal of Industrial Economics, Volume 21, Number 3, 1973. pp. 209–235.
21.
→ GrilichesZ., Patent Statistics as Economic Indicators: A Survey”, Journal of Economic Literature, Volume 28, December 1990, pp. 1661–1707.
22.
HayD.A.MorrisD.J., Industrial Economics: Theory and Evidence, (New York: Oxford University Press, 1979).
23.
LevittB.MarchJ.G., Chester I. Barnard and the Intelligence of Learning, in WilliamsonOliver E. ed., Organization Theory, (New York: Oxford University Press, 1990), pp. 11–37.
24.
KamienM. I.SchwartzN. L., “Market Structure, Elasticity of Demand, and the Incentive to Invest,”Journal of Law and Economics, Volume 13Number 1, 1970.
25.
→ KamienM. I.SchwartzN. L., “Market Structure and Innovation: A Survey,”Journal of Economic Literature, Volume 13, Issue 1, March 1975, pp. 1–37.
26.
KolassaE. M., Elements of Pharmaceutical Pricing, (Binghamton, NY: The Haworth Press, 1997).
27.
LevyR., The Pharmaceutical Industry: A Discussion of Competitive and Antitrust Issues in an Environment of Change, (Washington DC: Bureau of Economics Staff Report, Federal Trade Commission, March 1999).
28.
MansfieldE., The Economics of Technology Change, (New York: Norton, 1968).
29.
MansfieldE., Basic Research and Productivity Increases in Manufacturing,”The American Economic Review, Volume 70, Issue 5, December 1980, pp. 863–873.
30.
MansfieldE., “Technological Change and Market Structure: An Empirical Study,”American Economic Review; Volume 73, Issue 2, May 1983, pp. 205–209.
31.
MansfieldE., “Patents and Innovation: An Empirical Study,”Management Science, Volume 32, Number 2, February 1986, pp. 173–181.
32.
MansfieldE., “Industrial R&D in Japan and the United States: A Comparative Study,”American Economic Review, Volume 78, Issue 2, May 1988, pp. 223–228.
33.
MeasdayW., The Pharmaceutical Industry, in AdamsWalter, ed., The Structure of American Industry, Fifth Edition, (New York: Macmillan Publishing Co., Inc, 1977), pp. 250–284.
34.
NAE, The Competitive Status of the U.S. Pharmaceutical Industry: The Influences of Technology in Determining Industrial Competitive Advantage, (Washington, DC: National Academy Press, 1983).
35.
PakesA., “Comments and Discussion on Richard E. Caves, Michael D Whinston, and Mark A. Hurwitz, “Patent Expiration, Entry, and Competition in the U.S. Pharmaceutical Industry,”Brookings Papers on Economic Activity, 1991, pp. 1–45.
36.
ReinganumJ., “Practical Implications of Game Theoretic Models of R&D,”American Economic Review, Volume 74, Issue 2, May 1984, pp. 61–66.
37.
PhillipsA., “Concentration, Scale and Technological Change in Selected Manufacturing Industries, 1899–1939,”Journal of Industrial Economics, June 1956.
38.
SchererF.M., New Perspectives on Economic Growth and Technological Innovation, (Washington, DC: Brookings Institution Press, 1999).
39.
SchererF.M., “Pricing, Profits, and Technological Progress in the Pharmaceutical Industry,”Journal of Economic Perspectives, Volume 7, Number 3, Summer 1993, pp 97–115.
40.
SchererF.M.RossDavid, Industrial Market Structure and Economic Performance, Third Edition, (Boston: Houghton Mifflin Company, 1990).
41.
SchererF.M., Industrial Market Structure and Economic Performance, Second Edition, (Chicago: Rand McNally College Publishing Company, 1980).
42.
→ SchererF.M., “Research and Development Resource Allocation Under Rivalry,”The Quarterly Journal of Economics, Volume 81, Number 3, August 1967, pp. 359–394.
43.
SchwartzmanD., Innovation in the Pharmaceutical Industry, (Baltimore, MD: Johns Hopkins University Press, 1976).
44.
SchweitzerS.O., Pharmaceutical Economics and Policy, (New York: Oxford University Press, 1997).
45.
ShutF.T.Van BergeijkP.A.G., “International Price Discrimination: The Pharmaceutical Industry,”World Development, Volume 14, Number 9, 1986, pp. 1141–1150.
46.
TaggartJ., The World Pharmaceutical Industry, (London: Routledge, 1993).
47.
ThomasL.G., “Implicit Industrial Policy: The Triumph of Britain and the Failure of France in Global Pharmaceuticals,”Industrial and Corporate Change, Volume 3, Number 2, 1994, pp. 451–489.
48.
ThomasL.G., “Industrial Policy and International Competitiveness,” InCompetitive Strategies in the Pharmaceutical Industry, edited by HelmsR.B. (Washington, DC: AEI Press, 1996), pp. 107–129.
49.
→ ThompsonP.WaldoD., “Process versus Product Innovation: Do Consumption Data Contain Any Information?”Southern Economic Journal, Volume 67Number 1, 2000, pp. 155–170.
50.
TiroleJ., The Theory of Industrial Organization, (Cambridge, MA: The MIT Press, 1997).
51.
USDC: A Competitive Assessment of the U.S. Pharmaceutical Industry (United States Department of Commerce, Westview Press, 1986).
